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An antibody that specifically recognized phosphothreonine 72 in ets-2 was used to determine the phosphor-
ylation status of endogenous ets-2 in response to colony-stimulating factor 1 (CSF-1)/c-fms signaling. Phos-
phorylation of ets-2 was detected in primary macrophages, cells that normally express c-fms, and in fibroblasts
engineered to express human c-fms. In the former cells, ets-2 was a CSF-1 immediate-early response gene, and
phosphorylated ets-2 was detected after 2 to 4 h, coincident with expression of ets-2 protein. In fibroblasts, ets-2
was constitutively expressed and rapidly became phosphorylated in response to CSF-1. In both cell systems,
ets-2 phosphorylation was persistent, with maximal phosphorylation detected 8 to 24 h after CSF-1 stimula-
tion, and was correlated with activation of the CSF-1 target urokinase plasminogen activator (uPA) gene.
Kinase assays that used recombinant ets-2 protein as a substrate demonstrated that mitogen-activated protein
(MAP) kinases p42 and p44 were constitutively activated in both cell types in response to CSF-1. Immune
depletion experiments and the use of the MAP kinase kinase inhibitor PD98059 indicate that these two MAP
kinases are the major ets-2 kinases activated in response to CSF-1/c-fms signaling. In the macrophage cell line
RAW264, conditional expression of raf kinase induced ets-2 expression and phosphorylation, as well as uPA
mRNA expression. Transient assays mapped ets/AP-1 response elements as critical for basal and CSF-1-
stimulated uPA reporter gene activity. These results indicate that persistent activation of the raf/MAP kinase
pathway by CSF-1 is necessary for both ets-2 expression and posttranslational activation in macrophages.
Macrophage colony-stimulating factor 1 (CSF-1) controls
the proliferation and differentiation of cells of the mononu-
clear phagocyte cell lineage. The actions of CSF-1 are medi-
ated through an integral membrane receptor tyrosine kinase,
the product of the c-fms proto-oncogene (22). As with other
tyrosine kinase receptors, ligand binding leads to c-fms auto-
phosphorylation, assembly of phosphotyrosine-dependent sig-
naling complexes, and the subsequent activation of signal
transduction pathways (25). Pathways controlled by CSF-1/c-
fms include phosphatidylinositol 3-kinase (23), JAK-STATs
(19), c-src-related kinases (6), and the ras pathway (3, 7). The
latter two pathways have been demonstrated to be critical for
the mitogenic action of CSF-1 (3, 6, 15).
CSF-1 stimulation results in the stable, persistent expression
of specific genes, for example, the urokinase plasminogen ac-
tivator (uPA) gene, in mature macrophages or in fibroblasts
engineered to express c-fms (3, 14, 27). The uPA gene encodes
an extracellular protease involved in cellular migration in many
cell types, including metastatic tumor cells (2) and macro-
phages (5, 27).
The uPA promoter contains regions conserved across spe-
cies up to 8.2 kb 59 to the transcription start site (1, 5, 9).
Within these regions of homology, two compound ets/AP-1
growth factor- and oncogene-responsive elements have been
identified at 22.4 and 26.9 kb upstream of the transcription
initiation site (1, 9, 27). In transient transfections, oncoprotein
ras collaborates with either ets-1 or ets-2 to superactivate the
uPA promoter via the compound ets/AP-1 enhancer located at
22.6 kb relative to the transcription initiation site (34). Col-
laboration between ras and exogenously expressed ets factors
depends on ras-dependent phosphorylation at threonine resi-
dues Thr 38 and Thr 72 in ets-1 and ets-2, respectively (34).
The Thr 38 residue of ets-1 has been shown to be phosphor-
ylated in a CSF-1-dependent manner in NIH 3T3 cells that
exogenously express both ets-1 and c-fms (21). The phosphor-
ylation sites are contained in a 100-amino-acid domain that is
conserved between ets-1 and ets-2 and also in the Drosophila
melanogaster protein pointed P2 (4, 20). The conserved N-
terminal domain of the ets factor pointed P2 has been shown to
be a nuclear target for ras signaling pathways critical for dif-
ferentiation of the R7 photoreceptor cell in Drosophila, and
thus defines a target for ras signaling pathways that is con-
served through evolution from flies to humans (4, 20).
One well-characterized effector pathway activated by the
ras-GTP complex is the raf/MEK-1/mitogen-activated protein
(MAP) kinase pathway (16, 31). However, the exact identity of
the ras effector pathways that CSF-1/c-fms engage to persis-
tently activate the uPA promoter have not been defined. The
ras/MAP kinase pathway has been shown to activate TCF/elk-1
ets family transcription factors, but these events occur early
after growth factor stimulation and result in regulation of im-
mediate-early genes such as c-fos (reviewed in reference 31). In
PC-12 cells, activation of trkA has been shown to sustain ac-
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tivation of ras and MAP kinases p42 and p44 over several
hours, leading to the proposition that the duration and
strength of the ras signal are the critical variables that distin-
guish how cells interpret ras/MAP kinase signals generated by
different environmental stimuli (reviewed in reference 16).
In the present study, we present evidence for a signaling
cascade initiated by CSF-1/c-fms in either macrophages or
heterologous cells that ectopically express c-fms. This pathway
involves stimulation of the ras pathway, resulting in continuous
activation of MAP kinases p42 and p44 and stable phosphor-
ylation of ets-2 at threonine 72, events that are correlated with
the induction of uPA transcription by CSF-1.
MATERIALS AND METHODS
Cell culture and RNA analysis. NIH 3T3 cells containing genes expressing
c-fms protein were grown in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal calf serum (FCS). Prior to stimulation with CSF-1 (1 U 5 0.01 ng) or
platelet-derived growth factor (PDGF, BB isoform; Upstate Biotechnology,
Inc.), cells were grown in DMEM with 0.1% FCS for 16 to 24 h. Cells were
stimulated with 104 U of CSF-1 per ml (27). RAW264 cells were maintained in
RPMI media containing heat-inactivated 5% FCS. RAW264 cells expressing the
estrogen receptor-active raf kinase fusion protein were obtained from Julie
Hambleton and Tony DeFranco and were stimulated with b-estradiol (1027 M)
as described previously (11). The isolation of bone marrow-derived macrophages
(BMMs) has been previously described (27), and the cells were grown in RPMI
media containing 10% FCS and 104 U of CSF-1 per ml. For the experiments
described here, BMMs were deprived of CSF-1 for 16 to 24 h and then restim-
ulated with 104 U of CSF-1 per ml as indicated in the figure legends.
For experiments with the specific MEK-1 inhibitor PD98059, serum-starved
cells were treated with the drug at a final concentration of 50 mM (10) for 15 min
prior to addition of CSF-1. The drug was dissolved in dimethyl sulfoxide, and
control cells were treated with vehicle alone.
RNA isolation and Northern blotting were performed as previously described
(14, 27).
Production of anti-phosphopeptide T72 ets-2 antibody and Western blotting.
The peptides LPLL(p-T)PCS and LPLLTPCSKA corresponding to amino acids
68 to 77 of human ets-2 were synthesized. The position of the phosphate at
threonine 72 was confirmed by nuclear magnetic resonance. The phosphopeptide
was coupled to keyhole limpet hemocyanin and used to immunize two New
Zealand White rabbits. Collected serum was pooled and passed over a column to
which the nonphosphopeptide was coupled, and material that did not bind to this
column was collected and passed over a phosphopeptide affinity column. Bound
material was eluted from this second column with glycine (pH 2) buffer, dialyzed
against phosphate-buffered saline and stored at 270°C before use. Polyclonal,
phosphorylation-independent ets-2 antibodies were produced by immunization
of rabbits with a recombinant ets-2 protein corresponding to amino acid residues
60 to 167 [ets-2(60–167)].
Western blotting was performed with nitrocellulose membranes and the ECG
detection system (Amersham) as previously described (17, 34).
In-gel and MAP kinase assays. The substrate for both in-gel kinase and MAP
kinase assays was the portion of human ets-2 corresponding to amino acid
residues 60 to 167. This protein was expressed as a six-histidine-tagged recom-
binant protein in Escherichia coli K-12 by using the pET15b expression vector
system and was purified to .95% purity by nickel-Sepharose affinity chromatog-
raphy. Versions of the protein with either threonine or alanine at position 72
were produced and purified.
The in-gel and MAP kinase assays have been described in detail elsewhere
(17). For in-gel kinase assays, 100 mg of total protein derived from BMMs or
RAW264 cells was subjected to electrophoresis through a 12.5% acrylamide gel
which had been copolymerized with 500 mg of either the threonine 72 or alanine
72 versions of ets-2 protein per ml. After electrophoresis, the gel was subjected
to a denaturation-renaturation procedure, the in-gel kinase reaction was per-
formed, and the gel was subjected to autoradiography for 24 h (17).
An anti-MAP kinase antibody coupled to Sepharose beads was used for the
immune kinase experiments (Santa Cruz Biochemicals, Santa Cruz, Calif.). The
immune complex obtained from incubation of cell extracts with this antibody was
suspended in 30 ml of kinase buffer (20 mM HEPES [pH 7.2], 10 mM MgCl2, 1
mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 mg of leupeptin per
ml, 10 mg of aprotinin per ml, 1 mM orthovanadate, 1 mM EGTA, 10 mM
sodium fluoride, 1 mM tetrasodium pyrophosphate, 0.1 mM b-glycerophos-
phate) that contained 1 mg of the purified His-tagged ets-2 protein corresponding
to amino acids 60 to 167 and 5 mCi of [g-32P]ATP. After incubation at room
temperature for 30 min, the reaction was terminated by addition of sodium
dodecyl sulfate (SDS) sample buffer and boiling. The supernatant was run on
denaturing gels and analyzed by autoradiography. In some experiments, as indi-
cated in the figure legends, cold ATP was included in the kinase reaction. For
these experiments, phosphorylation of threonine 72 in the ets-2 substrate was
determined by Western blotting with the antiphosphopeptide ets-2 antibody
described above.
The jun kinase assays were performed with an influenza virus hemagglutinin
(HA)-tagged version of p55-JNK2 and glutathione S-transferase (GST)–N-ter-
minal c-jun recombinant proteins (residues 1 to 79) as previously described (13).
Both wild-type (S63/S73) and mutated (S63/A73) versions of c-jun were em-
ployed (13).
Plasmids and transient transfections. The parent plasmid for the murine uPA
promoter-luciferase reporters was pGL2-B (Promega). The construction of the
28.2, 26.6, 26.6 Dets/AP-1, and 2114 luciferase reporter plasmids has been
previously described (1, 27). The 24.2, 22.6, and 22.2 reporters were derived
from the 26.6 plasmid by digestion with HindIII, EcoRV, or BglII restriction
sites located at these positions in the 26.6 plasmid. The mouse c-fms cDNA (3.7
kb) was placed into the simian virus 40 expression vector pECE (27). The
fms-pECE plasmid was obtained from Changmin Chen (Centre for Molecular
and Cellular Biology, University of Queensland, Queensland, Australia). Elec-
troporation of RAW264 cells and determination of luciferase activity following
transfection were performed as previously described (27).
RESULTS
Recombinant ets-2 protein is a specific substrate for puri-
fied MAP kinases p42 and p44 in vitro. In work that depended
on transient transfection systems, we demonstrated that thre-
onine 72 of ets-2 was phosphorylated in a ras-dependent fash-
ion (34). In an attempt to define kinases that catalyze phos-
phorylation of this site in ets-2 in vitro, an N-terminal region of
ets-2 corresponding to the region conserved in the Drosophila
pointed P2 protein (amino acids 60 to 167) was overexpressed
as a six-histidine-tagged fusion protein in bacteria. The fusion
protein was subsequently purified and used as a substrate for in
vitro kinase reactions. Purified, recombinant MAP kinase p44
could utilize this portion of ets-2 as a substrate (Fig. 1A, lane
1). A recombinant ets-2 protein containing the Ala 72 substi-
tution was not used as a substrate by MAP kinase p44 (Fig. 1A,
lane 2). Furthermore, phosphoamino acid analysis of the 32P-
labeled threonine 72 ets-2(60–167) protein revealed exclusive
phosphorylation at threonine (data not shown). Identical re-
sults were obtained with purified MAP kinase p42 (data not
shown).
In contrast, the MAP kinase family member p55-JNK2 (13)
did not utilize the ets-2 recombinant protein (Fig. 1B lane 3) as
a substrate under conditions where the N-terminal region of
c-jun (residues 1 to 79) could be phosphorylated in vitro (Fig.
1B, lanes 1 and 2). In these experiments, the ets-2 protein was
a poorer substrate than even the c-jun substrate that lacked the
major phosphorylation sites at positions S63 and S73 (Fig. 1B,
lane 2), which was still detectably phosphorylated at minor
sites by JNK2 as previously reported (13). Additionally, both
MAP kinase p38 (32) and the proline-directed kinase cdk4
were unable to catalyze phosphorylation of the ets-2 threonine
72 substrate in vitro (data not shown).
Production and characterization of antiserum specific for
ets-2 phosphothreonine 72. In order to directly measure the
phosphorylation of endogenous ets-2 at amino acid position
threonine 72, an antibody that was specific for the phosphor-
ylated threonine residue was developed. For this purpose, the
peptide PLL-pT-PCSKA (corresponding to amino acids 69 to
77 of ets-2) was synthesized and used to produce polyclonal
rabbit serum. Following affinity purification (see Materials and
Methods), the specificity of the antibody for detecting phos-
phothreonine 72 ets-2 in Western blotting experiments was
tested with recombinant ets-2 proteins corresponding to amino
acids 60 to 167.
For these experiments, the ets-2 region was incubated in
vitro with nonradioactive ATP and activated MAP kinase p44
(Fig. 1C). These experiments showed that only wild-type thre-
onine 72 protein which had been incubated with the MAP
kinase preparation was recognized by the antibody (lane two
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versus lane 1 in Fig. 1C). Proteins containing the A72 substi-
tution were not recognized by the antibody whether MAP
kinase was present or absent (lanes 3 and 4). A second non-
discriminating (i.e., phosphorylation independent) antiserum
directed against the ets-2 N-terminal region (amino acids 60 to
167) was also produced. When the blot shown in Fig. 1C was
stripped and reprobed with the second antibody, equal loading
of the recombinant proteins could be demonstrated (Fig. 1D).
The phosphopeptide-specific anti-peptide antibody did not re-
act with blots that contained 10 mg of recombinant unphos-
phorylated threonine 72 protein per lane, nor did it react with
other phosphoproteins, for example, the N-terminal region of
c-jun (data not shown).
Persistent phosphorylation of ets-2 in response to CSF-1/c-
fms signaling in NIH 3T3 cells and in primary macrophages.
The anti-phosphopeptide T72 ets-2 antibody was used to de-
termine the phosphorylation status of endogenous ets-2 in
NIH 3T3 cells that express the human c-fms receptor tyrosine
kinase (23, 24). Activation of c-fms tyrosine kinase activity by
CSF-1 results in the activation of ras signaling pathways and
the persistent activation of ras-responsive genes (3, 14, 27). For
example, the activation of uPA mRNA expression in these cells
following CSF-1 stimulation was demonstrated in Fig. 2A. In
this experiment, Northern analysis reveals that uPA expression
was stimulated within 30 min following growth factor treat-
ment and that the expression of this mRNA persisted after 24 h
of stimulation. In contrast, stimulation of the same NIH 3T3
cell line with PDGF resulted in only transient stimulation of
uPA mRNA, with maximal stimulation after 30 min of PDGF
treatment (Fig. 2A). We have previously reported this differ-
ence in the ability of CSF-1 and PDGF to stimulate the ex-
pression of ras-responsive genes in NIH 3T3 cells (3). Thus, if
ets-2 is involved in growth factor-induced activation of uPA
expression, it should be rapidly phosphorylated in response to
FIG. 1. MAP kinases p42 and p44 phosphorylate position threonine 72 of
ets-2 in vitro. (A) Recombinant ets-2 proteins corresponding to amino acids 60
to 167 that contained either threonine 72 or alanine 72 (200 ng of protein, lanes
1 and 2, respectively) were incubated with [g-32P]ATP and purified, activated
MAP kinase p44 for 30 min and separated on an SDS-15% polyacrylamide gel.
Autoradiography was performed for 12 h. (B) In a parallel experiment, HA-
tagged JUNK2 was expressed in NIH 3T3 cells, immunoprecipitated, and used in
immune kinase assays with an N-terminal jun-GST fusion protein (amino acids
1 to 79), a jun-GST protein with residues 63 and 73 mutated from serine to
alanine, or the threonine 72 version of ets-2(60–167) (200 ng of each protein,
lanes 1 to 3, respectively). Autoradiography was performed for 12 h. (C and D)
Western blot of recombinant human ets-2 proteins (amino acids 60 to 167) with
threonine at position 72 (lanes 1 and 2) or alanine at position 72 (lanes 3 and 4).
The proteins (200 ng) were incubated with nonradioactive ATP in the absence
(lanes 1 and 3) or presence (lanes 2 and 4) of activated MAP kinase p42 (Upstate
Biotech, Inc.) for 30 min. The blot was probed with affinity-purified anti-phos-
phopeptide T72 antibody (C [see Materials and Methods]). The same blot was
stripped and probed with polyclonal antibody directed against ets-2 residues 60
to 167 (D).
FIG. 2. Kinetics of uPA mRNA induction and phosphorylation of ets-2 at
threonine 72 in response to CSF-1/c-fms signaling in NIH 3T3 cells. (A) North-
ern blot of total RNA isolated from NIH 3T3 cells expressing c-fms following
stimulation with CSF-1 and PDGF (2 ng/ml) for the times indicated (in hours)
and probed with a mouse uPA probe (upper panel) or a g-actin probe (lower
panel). (B) Nuclear protein extracts were prepared from NIH 3T3 cells express-
ing c-fms following stimulation with CSF-1 for the times indicated (in hours).
Extracts were run on a 10% SDS gel and Western blotted with the anti-pT72
ets-2 antibody (upper panel). The top arrow indicates the predicted location of
ets-2 (54 kDa), and the lower arrow indicates a second ets-2-related band (45
kDa). The same samples in panel B were run on a second gel and probed with
a nondiscriminating ets-2 antibody directed against amino acids 60 to 167 (bot-
tom panel). (C) Nuclear protein extracts prepared from NIH 3T3 cells stimu-
lated with 2 ng of PDGF (BB isoform) per ml for the times indicated (in hours)
were analyzed by Western analysis with the anti-pT72 antibody, as described
above. Only the 54-kDa form of ets-2 was detected (arrow). (D) NIH 3T3 cells
expressing wild-type c-fms Y809 (lanes 1 to 4) or the c-fms F809 protein (lanes
5 to 7) were stimulated for increasing periods of time with CSF-1 as indicated (in
hours). Nuclear protein extracts were prepared and analyzed by SDS-polyacryl-
amide gel electrophoresis (10% polyacrylamide gel) followed by Western blot-
ting with the anti-phosphopeptide T72 ets-2 antibody.
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CSF-1 or PDGF stimulation, but in addition it should remain
phosphorylated for extended periods following CSF-1 treat-
ment.
Nuclear extracts were prepared from the NIH 3T3 cells
expressing c-fms following CSF-1 treatment for increasing pe-
riods of time. These samples were analyzed by Western blot-
ting with the anti-phosphopeptide T72 affinity-purified anti-
body (Fig. 2B). Specific binding of the antibody was not seen in
the extracts prepared from serum-starved cells. However, the
antibody detected a major band of 54 kDa, the predicted size
for ets-2, within 30 min of CSF-1 treatment (Fig. 2B, upper
panel, upper arrow). This band was observed throughout the
CSF-1 time course up to 24 h after CSF-1 treatment. If anti-
body incubations were performed in the presence of the phos-
phopeptide used for immunization, the 54-kDa band was not
detected (data not shown). The nuclear samples were analyzed
with a nonphosphopeptide-selective ets-2 antibody raised
against a recombinant ets-2 protein comprising amino acids 60
to 167 (Fig. 2B, lower panel). This antibody detected the same
54-kDa major species in all samples, including the serum-
starved samples (Fig. 2B, lower panel, upper arrow). The 54-
kDa band was not detected in cytoplasmic extracts (data not
shown).
In contrast to the results obtained with CSF-1, treatment of
the same NIH 3T3 cell line with PDGF resulted in a transient
stimulation of ets-2 phosphorylation (Fig. 2D). The phosphor-
ylation of ets-2 was maximal within 30 min following PDGF
treatment and was undetectable after 8 to 12 h of treatment.
The steady-state levels of ets-2 protein, determined by using
the nondiscriminating antibody, were not affected by PDGF
treatment (data not shown). Thus, ets-2 was phosphorylated at
position threonine 72 in a manner consistent with the kinetics
of activation of uPA mRNA by either CSF-1 or PDGF.
A mutation at an autophosphorylation site at tyrosine resi-
due 809 in the human c-fms (809Y3809F) protein selectively
abrogates the ability of ligand-activated receptor to stimulate
mitogenic growth of NIH 3T3 cells and to stimulate expression
of ras-responsive genes like that coding for uPA (14, 27). The
F809 receptor also failed to stimulate the conversion of ras to
the GTP complex, a conversion the wild-type Y809 receptor
efficiently carries out (20a). This receptor failed to activate
phosphorylation of ets-2 (Fig. 2D), providing an additional
correlation between ets-2 phosphorylation and receptor-de-
pendent activation of persistent gene expression.
In addition to the major band migrating at the predicted size
for ets-2, a smaller, 45-kDa band was detected by both anti-
bodies used (lower arrow in Fig. 2B and D). This band was
especially prominent after 12 to 24 h of CSF-1 stimulation of
cells. The identity of this cross-reacting species is under inves-
tigation, but preliminary data indicate that it may be derived by
proteolysis of the 54-kDa protein species (data not shown).
The c-fms gene is usually predominantly expressed in mono-
cytes and macrophages in adult mammals (22), and we have
previously implicated ets-2 in uPA activation in this cell type
(27). In BMMs deprived of CSF-1, the kinetics of uPA induc-
tion were delayed following restimulation with CSF-1 with
respect to the situation observed in the artificial NIH 3T3
system. In BMMs, uPA expression was induced after 4 h and
was maximal by 8 h following stimulation (Fig. 3A). When
nuclear extracts from BMMs stimulated with CSF-1 were an-
alyzed, the kinetics of ets-2 phosphorylation were also found to
be delayed relative to those in the NIH 3T3 system, with little
of the phosphothreonine 72 form of ets-2 seen until 4 to 8 h of
CSF-1 treatment (Fig. 3B, upper panel, upper arrow). The
phosphothreonine 72 form of ets-2 was observed following 12
to 24 h of growth factor stimulation and in cells continuously
grown in the presence of CSF-1 (data not shown). When these
samples were analyzed with nondiscriminating antibody [anti-
ets-2(60–167) antibody], it was observed that in contrast to
NIH 3T3 cells, ets-2 was not expressed in CSF-1-deprived
BMMs, but was detectable after 4 h of CSF-1 treatment (Fig.
3B, lower panel, upper arrow).
As in the NIH 3T3 cells, the faster-migrating 45-kDa cross-
reactive protein was again detected (Fig. 3B, lower arrows). In
addition, the anti-phosphopeptide T72 antibody specifically
cross-reacted with a protein with an apparent molecular mass
of 100 kDa (Fig. 3B, arrowhead). This 100-kDa species was
induced within 1 h following CSF-1 stimulation of BMMs and
was detected at 8 h after stimulation as well. However, the
100-kDa protein was not recognized by the non-phosphopep-
tide ets-2 antibody (Fig. 3B, lower panel). The nature of the
100-kDa species is currently under investigation.
The expression and phosphorylation of ets-2 in the macro-
phage cell line RAW264 were also analyzed. CSF-1 does not
stimulate uPA transcription in these cells (27), and ets-2 ex-
pression was not detected with either phosphopeptide ets-2 or
nondiscriminating ets-2 antibodies, regardless of whether
CSF-1 was added to the cell culture medium (Fig. 3B, lanes R).
The anti-phosphopeptide Thr 72 cross-reacting 100-kDa band
was also absent in RAW264 cells.
FIG. 3. Kinetics of uPA mRNA induction and phosphorylation of ets-2 at
threonine 72 in response to CSF-1/c-fms signaling in primary macrophages. (A)
Northern blot of total RNA isolated from BMMs following stimulation with
CSF-1 (time in hours as indicated; p, cells grown continually in CSF-1 without
starvation) and probed with mouse uPA (upper panel) or an 18S RNA probe
(lower panel). (B) Nuclear protein extracts were prepared from BMMs following
stimulation with CSF-1 for the times indicated. Extracts were run on a 10% SDS
gel and Western blotted with the anti-phosphopeptide T72 ets-2 antibody (upper
panel). The two arrows indicate the predicted location of ets-2 (54 kDa) and a
second related 45-kDa band, as described above, while the large arrowhead
indicates the position of a 100-kDa cross-reacting protein species. The same
samples as those used in the upper panel were analyzed in parallel with a
nondiscriminating ets-2 antibody directed against amino acids 60 to 167 (bottom
panel). Lanes R and T contained extracts prepared from RAW264 cells (negative
control) or NIH 3T3 cells that express c-fms (positive control), respectively, both
treated with CSF-1 for 24 h prior to extract preparation. Arrowheads indicate the
predicted position of ets-2 p54 and the related 45-kDa protein, as described
above.
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MAP kinase p42 and p44 activity correlates with ets-2 phos-
phorylation in BMMs and in NIH 3T3 cells. Previous work has
indicated that CSF-1 stimulation of MAP kinase p42 and p44
activity in macrophages is transient, with a peak of activity
within 10 to 15 min following growth factor stimulation (12),
suggesting that these kinases may not be the ets-2 kinase
present in these cells. In order to identify kinases capable of
phosphorylating ets-2 in primary macrophages, in-gel kinase
assays were performed with the ets-2(60–167) recombinant
protein as a substrate (Fig. 4A, left panel, lanes 1 to 6). In
extracts derived from BMMs, the two major specific protein
species detected by this assay migrated with mobilities of 42
and 44 kDa. Within 1 min of addition of CSF-1, the activity of
these two kinases was induced. In addition, the 42-kDa kinase
remained active following 4 h of CSF-1 stimulation, indicating
that activation of this kinase was persistent in BMMs. In
RAW264 cells treated with CSF-1, there was five- to sevenfold-
less induction of this ets-2 kinase activity (Fig. 4A, lanes 7 to
12). When the Ala 72 form of the ets-2 pointed P2 domain was
used as a substrate in this analysis, the p42 and p44 bands were
not detected (Fig. 4A, right panel). In addition to the two
specific bands, a number of constitutive phosphorylated bands
were detected. All of these were also observed with the Ala 72
mutant ets-2 pointed domain (Fig. 4A, right panel) and prob-
ably represent autophosphorylation of resident kinases.
In order to confirm that the specific protein species detected
in the in-gel kinase assay were MAP kinases p42 and p44,
immune kinase assays were performed with BMM cell lysates
with antibody that specifically recognizes these two MAP ki-
nase species. Once again, the ets-2 recombinant protein was
utilized as a substrate. These data were consistent with those of
the in-gel kinase assays, demonstrating that MAP kinase was
detected within 30 min of CSF-1 stimulation and that activity
persisted up to 24 h following stimulation (Fig. 4B, upper
panel). Analysis of these samples by Western blotting with an
anti-MAPK kinase antibody revealed that the level of MAP
kinase did not change during the CSF-1 time course (Fig. 4B,
lower panel). Consistent with the in-gel kinase results, signifi-
cant MAP kinase activity was not seen when such an assay was
performed with CSF-1-treated RAW264 cells (data not
shown).
The immune kinase assays as described above were repeated
with lysates prepared from NIH 3T3 cells that express c-fms
(Fig. 5A). Little MAP kinase activity was detected in CSF-1-
starved cells, but persistent activation of MAP kinase activity
was seen from 30 min up to 24 h following CSF-1 treatment
(Fig. 5A, left panel). MAP kinase expression remains constant
over this time course, as revealed by Western analysis with the
same MAP kinase-specific antibody as that used above (Fig.
5A, right panel). Stimulation of F809–c-fms/NIH 3T3 cells with
CSF-1 does not lead to increased MAP kinase activity (Fig.
5B), although Western analysis indicated that MAP kinase
levels in these cells were comparable to those seen in the
Y809–c-fms/NIH 3T3 cells (data not shown).
MAP kinases p42 and p44 are the major ets kinases detected
in c-fms/NIH 3T3 cells. To determine if kinases other than
MAP kinases p42 and p44 could be detected following CSF-1
stimulation, MAP kinase p42 and p44 activity was depleted by
five successive rounds of immune precipitation from lysates
prepared from CSF-1-stimulated c-fms/NIH 3T3 cell lysates
(Fig. 6A). This analysis revealed that after four rounds of
antibody treatment, .95% of MAP kinase activity was re-
FIG. 4. Kinetics of MAP kinase activation in response to CSF-1 stimulation
in primary macrophages. (A) In-gel kinase assays with the ets-2(60–167) threo-
nine 72 (left panel), or alanine 72 (right panel) protein as the substrate. BMMs
were starved of CSF-1 for 16 h and then stimulated with CSF-1 for 1, 5, 30, 60,
and 240 min (lanes 1 to 6). RAW264 cells were stimulated with CSF-1 for the
same times (lanes 7 to 12). For these experiments, the 12.5% acrylamide gel was
copolymerized with 500 mg of either the threonine 72 or alanine 72 versions of
ets-2 protein per ml as indicated. Arrows indicate the migration of the major
kinase bands identified in the BMMs at 42 and 44 kDa, when threonine 72
protein is used as a substrate. These bands are not seen in the gel containing the
alanine 72 version of the protein. (B) Immunoprecipitation kinase assays were
performed with BMMs that had been starved of CSF-1 for 16 h and then
stimulated with CSF-1 for the times indicated (in hours). MAP kinases p42 and
p44 were immunoprecipitated from 25 mg of whole-cell protein, and incorpora-
tion of 32P into the ets-2 threonine 72 protein substrate was measured in one-half
of the sample following electrophoresis in a 15% SDS gel (top panel). The other
half of the immune kinase assay was analyzed on a 10% SDS gel, and MAP
kinase p42 and p44 were detected by Western blotting with a specific polyclonal
antibody (bottom panel).
FIG. 5. Kinetics of MAP kinase activation in response to CSF-1 stimulation
in c-fms/NIH 3T3 cells. (A) Immunoprecipitation kinase assays were performed
with extracts from NIH 3T3 cells expressing c-fms and stimulated with CSF-1 for
various amounts of time, as indicated (in hours). MAP kinases were immuno-
precipitated from 25 mg of whole-cell lysates and incubated with recombinant
ets-2 protein (amino acids 60 to 167) and cold ATP. One-half of the kinase assays
were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-15% polyacryl-
amide gel) followed by Western blotting with the anti-phosphopeptide T72 ets-2
antibody (left panel). For select samples (as indicated), one-half of the kinase
assay was analyzed with an SDS-10% polyacrylamide gel, and MAP kinase p42
and p44 was detected by Western analysis (right panel). (B) Immunoprecipita-
tion-kinase assays were performed and analyzed as described above with extracts
from NIH 3T3 cells expressing either wild-type c-fms (lanes 1 to 4) or the c-fms
F809 mutant receptor (lanes 5 to 8). Samples were analyzed at the time points (in
hours) indicated.
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moved from the cell lysates (lanes 3 to 7). At the same time,
while ets kinase activity could be detected in the supernatant
recovered after the second round of immunoprecipitation, no
activity could be detected in the supernatant that was recov-
ered after the fourth round (lane 1 versus lane 2).
To further confirm that the raf/MEK-1/MAP kinase p42 and
p44 pathway was the major CSF-1-induced ets-2 kinase path-
way, phosphorylation of ets-2 in the presence of the specific
MEK-1 inhibitor PD98059 (10) was determined with the anti-
phosphopeptide T72 ets-2 antibody (Fig. 6B). This experiment
demonstrated that in fibroblasts expressing c-fms, PD98059
blocked ets-2 phosphorylation at both early (Fig. 6B, lane 2
versus lane 3) and late (Fig. 6B, lane 4 versus lane 5) times
following growth factor stimulation and also blocked CSF-1
stimulation of uPA mRNA expression (data not shown). At the
same time, ets-2 expression, as detected with the non-phos-
phopeptide-specific antibodies, was not affected by drug treat-
ment (Fig. 6C). The same experiments were attempted with
primary mouse BMMs, but ets-2 expression could not be de-
tected following treatment of cells with both CSF-1 and
PD98059 (data not shown). Within hours of exposure to the
drug PD98059, BMMs lose viability, as determined by trypan
blue dye exclusion, making it difficult to determine if the lack
of ets-2 expression was a specific or general effect of the drug.
Conditional expression of activated raf kinase in RAW264
cells induces ets-2 expression and phosphorylation and uPA
mRNA. CSF-1 is not able to stimulate ets-2 expression or
phosphorylation in RAW264 cells. In order to determine
where the defect in CSF-1 signaling occurs, RAW264 cells that
express an estrogen-inducible form of raf kinase were used to
activate MAP kinases in a CSF-1-independent fashion (11).
We reasoned that such an analysis would reveal whether the
signaling defect lies downstream or upstream of raf kinase.
Following estrogen treatment, analysis of uPA mRNA levels
indicated that this gene was induced within 2 h and maximally
stimulated 8 to 16 h after addition of estrogen (Fig. 7A, upper
panel), after correction for RNA sample loading (lower panel,
g-actin rehybridization control). Northern analysis also dem-
onstrated that ets-2 mRNA was induced in these cells follow-
ing stimulation of raf activity (data not shown).
The expression and phosphorylation status of ets-2 protein
were studied by Western blotting (Fig. 7B and C). Use of the
anti-phosphopeptide T72 ets-2 antibody demonstrated that
ets-2 was expressed and phosphorylated following activation of
raf kinase activity (Fig. 7B). As with CSF-1 treatment of sig-
naling-competent cells, both the p54 and p45 forms of ets-2
could be detected (see above). Use of the nondiscriminating
ets-2 antibody again demonstrated that both ets-2 bands were
detected. The kinetics of ets-2 expression and phosphorylation
paralleled expression of uPA mRNA.
In control experiments, b-estradiol had no effect on ets-2 or
uPA expression in either normal RAW264 cells or cells that
contained the estrogen receptor vector lacking the raf kinase
coding sequences (reference 11 and data not shown).
cis element requirements for CSF-1 induction of the uPA in
RAW264 cells. Given the results presented above, a possible
explanation for the failure of CSF-1 signaling to induce uPA
transcription in RAW264 cells is that the steady-state level of
receptor is insufficient to provide the signal required for sus-
tained activation of MAP kinases and subsequent phosphory-
FIG. 6. MAP kinases p42 and p44 are the major ets-2 kinase in c-fms/NIH
3T3 cells. (A) Immunodepletion of MAP kinase p42 and p44 activity in c-fms/
NIH 3T3 cells stimulated for 24 h with CSF-1. Five successive rounds of immu-
noprecipitation were performed to completely deplete MAP kinase activity, and
the precipitated kinase activity was measured by 32P incorporation into the
ets-2(60–167) substrate detected after SDS-PAGE (15% gel, lanes 3–7, respec-
tively). The kinase activities remaining in the supernatant following the second
and fourth rounds of immunoprecipitation (lanes 1 and 2, respectively) were also
measured by 32P incorporation into the ets-2(60–167) substrate. (B) Inhibition of
ets-2 phosphorylation by the MEK-1 inhibitor PD98059. NIH 3T3 cells that
expressed c-fms were serum starved for 24 h (lane 1) and then treated with CSF-1
and dimethyl sulfoxide (the carrier used for PD98059) for 4 or 24 h (lanes 2 and
4, respectively) or with the combination of CSF-1 and PD98059 for 4 of 24 h
(lanes 3 and 5, respectively). Cells were also treated with PD98059 alone for 24 h
(lane 6). Nuclear extracts were prepared, and one-half of the extract was ana-
lyzed by Western blotting with the anti-phosphopeptide ets-2 antibody. (C) The
second half of the samples described above was analyzed in parallel with the
nondiscriminating ets-2 antibody. Lanes 1 to 6 contained the samples in the same
order described above.
FIG. 7. Conditional expression of activated raf kinase in RAW264 cells in-
duces ets-2 expression and phosphorylation. RAW264 cells that express the
estrogen receptor-raf fusion protein (11) were treated with estrogen (1027 M)
for 2, 4, 8, or 16 h (lanes 2 to 5, respectively) and compared to untreated cells
(lane 1). (A) RNA was prepared from the untreated and stimulated cells and
analyzed by Northern blotting with the uPA-specific probe (upper panel; the
arrow indicates the position of uPA mRNA). The blot was rehybridized with an
actin-specific probe to control for RNA loading (lower panel). (B and C) Protein
extracts were prepared from the untreated and stimulated cells and analyzed by
Western blotting with the anti-ets-2 phosphopeptide T72 antibody (B) or the
nondiscriminating ets-2 antibody (C). Arrows indicate the positions of the p54
and p45 ets-2 proteins, respectively.
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lation of ets-2. Consistent with this hypothesis, previous studies
have shown that the level of CSF-1 binding sites per cell and
the level of c-fms mRNA are lower in RAW264 cells than in
BMMs (35) and that the relative transcription of c-fms in
run-on transcription assays is lower (27).
To determine if transient overexpression of c-fms from a
heterologous promoter would rescue CSF-1 induction of uPA
promoter activity, RAW264 cells were cotransfected with a
c-fms expression plasmid and a uPA reporter plasmid (Fig.
8A). Both CSF-1 and phorbol ester were able to stimulate the
uPA reporter, and the effects of the two agents were approx-
imately additive (Fig. 8A). Cells transfected with control ex-
pression plasmid lacking the c-fms cDNA and a uPA reporter
responded only to phorbol ester, and there was no interaction
between CSF-1 and phorbol ester (Fig. 8A).
The response of a series of uPA reporter plasmids to CSF-
1/c-fms activation was studied in order to determine the cis
requirements for cytokine activation (Fig. 8B). A construct
containing 8.2 kb of information upstream of the mRNA ini-
tiation site had maximal basal activity and was activated eight-
fold by CSF-1 in cells cotransfected with c-fms. The deletion
from 28.2 to 26.6 kb, which eliminates the distal ets/AP-1 site
at 26.9 kb (9), reduced both basal and CSF-1/c-fms-induced
promoter activities approximately twofold. Further deletions
to 24.2 and 22.6 had no significant effect on either basal or
CSF-1-induced activity of the uPA promoter. However, a de-
letion to 22.3, which eliminates a second ets/AP-1 element
located at 22.4 kb (27), resulted in a further eightfold reduc-
tion in both basal and CSF-1-induced promoter activity. De-
letion of the uPA upstream region to 2114 bp had no addi-
tional effect on either basal activity or the CSF-1/c-fms
response. However, site-directed deletion of the conserved ets/
AP-1 enhancer region located at 22.4 kb also reduced both
basal and CSF-1-stimulated activity seven- to eightfold (Fig.
8B, 26.6 D). Thus, the ets/AP-1 site located at 22.4 kb distal
to the uPA transcription initiation site is necessary, although
not sufficient, for maximal CSF-1 induction of uPA promoter
activity.
DISCUSSION
The data presented support a model in which CSF-1/c-fms
receptor ligation leads to prolonged activation of MAP kinases
p42 and p44, to sustained phosphorylation of ets-2 on residue
threonine 72, and to stable induction of uPA transcription.
These results emphasize a basic difference between macro-
phages and the fibroblast model for c-fms signaling and rein-
force the importance of studying c-fms action in the biologi-
cally relevant monocyte/macrophage background (15). In
macrophages, the expression of ets-2 is part of the CSF-1
immediate-early response, and both expression of this gene
and activation of the factor by phosphorylation are mediated
by the raf/MAPK kinase signaling pathway. Future studies will
be directed toward understanding the regulation of the ets-2
gene in macrophages. Activation of immediate-early MAP ki-
nase targets such as elk-1 (31, 32) or inactivation of repressors
such as the ets factor erf-1 (26) may be involved in the induc-
tion of the ets-2 promoter.
The transient transfection studies with RAW264 cells sup-
port the hypothesis that ets-2 is necessary for CSF-1 induction
of the uPA promoter. The ets/AP-1 element at 22.4 kb relative
to the transcription initiation site has been shown previously to
mediate the response to phorbol esters and oncoprotein ras in
these cells (27, 34). Mutation of this site, along with the dele-
tion of the region containing a fibroblast growth factor-respon-
sive ets/AP-1 site located at 26.9 kb (9), resulted in a 90 to
95% decrease in both basal and CSF-1-induced uPA promoter
activity. Transcription of another CSF-1-responsive gene in
macrophages, the scavenger receptor, has also been shown to
be dependent on redundant promoter and enhancer elements
that include ets/AP-1-type elements (18, 33), indicating that
common mechanisms control the expression of CSF-1 target
genes.
The dependence of the basal activity upon the ets/AP-1
elements was unexpected given that the ets-2 protein is not
detected in RAW264 cells. A potential explanation of the data
lies in the observation that RAW264 cells and primary macro-
phages are able to respond to unmethylated CpG residues
contained in the plasmid DNA used for the transfections (28).
The unmethylated DNA response is similar to the response
stimulated by bacterial lipopolysaccharide (LPS) (28, 29), and
both LPS and CpG DNA can mimic the ability of CSF-1 to
induce ets-2 expression and phosphorylation (29). Hence, the
basal activity of the uPA promoter in transfected RAW264
cells may be interpreted as a response to plasmid DNA, which
likely acts through the same ets/AP-1 elements.
The persistent activation of MAP kinases by CSF-1 in
BMMs contrasts with previous work where kinase activity was
FIG. 8. The ets/AP-1 enhancer is necessary for CSF-1 induction of uPA
reporter gene activity in RAW264 cells. (A) RAW264 cells were transiently
transfected with pGL2-uPA-6.6 with either the c-fms expression plasmid or the
empty parent plasmid, pECE. Where indicated, 104 U of CSF-1 per ml was
added immediately after electroporation, while 1027 M phorbol myristate ace-
tate (PMA) was added after 6 h, and cells were harvested after 24 h. (B)
RAW264 cells were transiently transfected with a series of uPA promoter and
enhancer mutations as represented in the first column. The D indicates the
deletion of the ets/AP-1 element from the 26.6-kb promoter. A c-fms expression
plasmid was included with the various uPA reporters in the transient transfec-
tion, cells were treated with or without 104 U of CSF-1 per ml for 24 h, and the
cell lysates were assayed for luciferase activity. Luciferase activity is presented as
relative light units per microgram of protein. The results of four experiments (A)
or three experiments (B), each performed in duplicate, are presented with bars
representing the standard error.
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reported to decline rapidly after an initial peak at 5 to 15 min
following CSF-1 treatment (12). The ets-2 substrate employed
in the present studies may be a more efficient monitor of
specific MAP kinase activity than other substrates commonly
used. The use of the ets-2 pointed P2 domain as a substrate has
the additional advantage that it distinguishes activation of p42
and p44 from the activation of other proline-directed kinases,
which were not able to phosphorylate this substrate. This is in
contrast to the ets factor elk-1 and related proteins which are
phosphorylated by multiple MAP kinase family members, in-
cluding MAP kinase p42/p44, JNK, and p38 (31, 32).
How is the persistent signal in response to CSF-1 main-
tained? The results obtained with RAW264 cells suggest an
answer to this question. In RAW264 cells, c-fms expression is
likely below a threshold that allows persistent engagement of
the ras/MAP kinase pathway and activation of the uPA pro-
moter, and transient overexpression of c-fms rescues the sig-
naling defect. In primary macrophages, CSF-1 and its receptor
are rapidly internalized and degraded following CSF-1 binding
so that there is a cycle of receptor-mediated ligand degradation
(reviewed in reference 22). Thus, the steady-state level of c-fms
could determine whether a transient or persistent signal is
engaged in response to CSF-1. Similarly, the failure of PDGF
to stimulate persistent phosphorylation of ets-2 in NIH 3T3
cells may reflect rapid turnover of the PDGF receptor with
respect to c-fms following growth factor treatment. Such argu-
ments are consistent with results obtained in other systems, for
example, increasing steady-state levels of the epidermal growth
factor or insulin receptors in PC-12 cells results in prolonged
activation of the ras/MAP kinase pathway and neuronal differ-
entiation of this cell type (8, 30).
In conclusion, the present studies indicate that CSF-1 action
involves the continual activation of MAP kinase activity, lead-
ing to transcription factor phosphorylation and selective acti-
vation of gene transcription. Studies of CSF-1 signaling pro-
vide one paradigm for understanding how tyrosine kinase
receptors trigger persistent signaling pathways as well as the
biological consequences of such prolonged signaling events.
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